Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,
and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government
operating status and resumption of normal operations can be found at opm.gov.
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma. Cohorts of patients will receive multiple ascending doses of intravenous DFRF4539A every 3 weeks or weekly. Patients exhibiting acceptable safety and evidence of clinical benefit may receive DFRF4539A for up to 17 cycles. Anticipated time on study treatment is 1 year or until disease progression or unacceptable toxicity occurs.
Safety: Incidence of adverse events [ Time Frame: approximately 3.5 years ]
Safety: Maximum tolerated dose/dose-limiting toxicities [ Time Frame: approximately 1.5 years ]
Recommended Phase II dose for every-3-week or weekly administration of DFRF4539A [ Time Frame: approximately 3.5 years ]
Secondary Outcome Measures
Immunogenicity: Serum antitherapeutic antibody levels [ Time Frame: approximately 3.5 years ]
Pharmacokinetics: Area under the concentration - time curve (AUC) [ Time Frame: approximately 3.5 years ]
Objective response, tumor assessments according to International Myeloma Working Group (IMWG) Uniform Response Criteria and/or European Bone Marrow Transplant (EBMT) Criteria [ Time Frame: approximately 3.5 years ]
Duration of objective response, defined as time from first documented objective response to progression or death of any cause [ Time Frame: approximately 3.5 years ]
Progression-free survival, defined as time from first study treatment (Cycle 1, Day 1) to disease progression or death during study or within 30 days after last dose of study drug, whichever occurs first [ Time Frame: approximately 3.5 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult patients; >/= 18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
Relapsed or refractory multiple myeloma for which no effective standard therapy exists
One of the prior therapies must have included a proteosome inhibitor or an immunomodulatory drug
Measurable disease as defined by protocol
Prior use of monoclonal antibody within 4 weeks before Cycle 1, Day 1
Treatment with radiotherapy, thalidomide, lenalidomide, bortezomib, any chemotherapeutic agent, or treatment with any investigational anti-cancer agent within 2 weeks prior to Cycle 1, Day 1
Toxicities from any previous treatment must be resolved prior to Cycle 1, Day 1, except for neuropathy
Completion of autologous stem cell transplant within 100 days prior to Cycle 1, Day 1
Prior allogeneic stem cell transplant
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
Grade > 1 peripheral neuropathy
Active infection at screening or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to Cycle 1, Day 1
Positive for hepatitis B, hepatitis C or HIV infection
Pregnant or lactating women or women who intend to become pregnant within the period of time of this study